<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
  xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
  xmlns:content="http://purl.org/rss/1.0/modules/content/"
  xmlns:atom="http://www.w3.org/2005/Atom">

  <channel>
    <title>SHTG Daily Digest — Weiss Lab</title>
    <link>https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/</link>
    <atom:link href="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/feed.xml" rel="self" type="application/rss+xml"/>
    <description>Daily research digest on severe hypertriglyceridemia, ANGPTL3, ANGPTL4, APOC3, and lipoprotein lipase. Auto-generated from PubMed for Ethan Weiss.</description>
    <language>en-us</language>
    <copyright>Ethan Weiss / Marea Therapeutics</copyright>
    <itunes:author>Ethan Weiss</itunes:author>
    <itunes:email>eweiss@mareatx.com</itunes:email>
    <itunes:owner>
      <itunes:name>Ethan Weiss</itunes:name>
      <itunes:email>eweiss@mareatx.com</itunes:email>
    </itunes:owner>
    <itunes:category text="Science"/>
    <itunes:explicit>false</itunes:explicit>
    <itunes:type>episodic</itunes:type>
    <image>
      <url>https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/cover.jpg</url>
      <title>SHTG Daily Digest</title>
      <link>https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/</link>
    </image>
    <itunes:image href="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/cover.jpg"/>
    <!-- Add new <item> blocks below this line, newest first -->
    <item>
      <title>SHTG Digest — Tuesday July 14, 2026</title>
      <description><![CDATA[A quiet cycle on both fronts — Part A offers three next-tier papers on FCS-gene carrier states and the ANGPTL axis rather than any top-journal blockbuster, while Part B has no genuinely new news: the period's two biggest Ionis stories (the Tryngolza sHTG label expansion and the Wainua ATTR-CM trial failure) were both already covered in the July 10 episode and have no material updates since.]]></description>
      <pubDate>Tue, 14 Jul 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-07-14</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-07-14.mp3"
        length="6458880"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday July 14, 2026</itunes:title>
      <itunes:duration>5:23</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday July 10, 2026</title>
      <description><![CDATA[No top-tier journal papers cleared the bar this cycle so Part A drops down a tier to three directly relevant clinical items on hypertriglyceridemia and LPL biology, while Part B is dominated by a single but consequential Ionis story — the surprise Phase 3 failure of Wainua in ATTR-CM, which isn't a lipid-program readout but is reshaping the competitive and investor picture for Ionis and Alnylam.]]></description>
      <pubDate>Fri, 10 Jul 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-07-10</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-07-10.mp3"
        length="8432160"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday July 10, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday July 7, 2026</title>
      <description><![CDATA[A thin cycle on both sides — the only new top-tier hit is a review on residual lipid risk beyond LDL (ANGPTL/apoC-III/FGF21 pathways get a mention), and there's no fresh industry news in the last 5 days beyond last week's Tryngolza sHTG approval, which was already covered.]]></description>
      <pubDate>Tue, 07 Jul 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-07-07</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-07-07.mp3"
        length="7343040"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday July 7, 2026</itunes:title>
      <itunes:duration>6:07</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday July 3, 2026</title>
      <description><![CDATA[A quiet cycle overall — no top-tier journal papers on our core targets cleared the bar and no genuinely new industry news broke in the last five days, so this episode leans on two next-best-tier papers (an ANGPTL3-inhibitor phase 3 extension and a pediatric SHTG risk-prediction study) while the Arrowhead/Ionis/Alnylam news front stayed silent beyond what's already been covered.]]></description>
      <pubDate>Fri, 03 Jul 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-07-03</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-07-03.mp3"
        length="4982400"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday July 3, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday June 30, 2026</title>
      <description><![CDATA[A quiet science week surfaces a novel APOC3 role in diabetic retinal angiogenesis and a diagnostic yield study for monogenic HTG, while the industry story remains Ionis' Tryngolza commercial launch into the 3.6-million-patient sHTG market following last week's FDA approval.]]></description>
      <pubDate>Tue, 30 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-30</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-30.mp3"
        length="5594304"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday June 30, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday June 26, 2026</title>
      <description><![CDATA[The week's dominant story is the FDA's June 24 approval of Ionis' Tryngolza (olezarsen) as the first-ever treatment for severe hypertriglyceridemia with a pancreatitis risk reduction claim; on the science side, three next-best-tier papers examine plozasiran's pharmacology, ApoC3's biphasic role across the MASLD spectrum, and urinary ANGPTL3 as a novel biomarker for podocyte injury.]]></description>
      <pubDate>Fri, 26 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-26</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-26.mp3"
        length="3794157"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday June 26, 2026</itunes:title>
      <itunes:duration>9:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday June 23, 2026</title>
      <description><![CDATA[A fresh meta-analysis of 14 APOC3-inhibitor trials confirms 80% reduction in acute pancreatitis risk alongside a compelling indirect head-to-head of olezarsen versus volanesorsen in FCS, while the most important industry event this cycle is the looming June 30 FDA decision on Tryngolza for severe hypertriglyceridemia.]]></description>
      <pubDate>Tue, 23 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-23</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-23.mp3"
        length="10545120"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday June 23, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday June 19, 2026</title>
      <description><![CDATA[A quiet breaking-news cycle on paper, but the lipid field is coiled for impact — a landmark Ionis FDA decision on olezarsen for severe hypertriglyceridemia is 11 days out, and fresh science clarifies who among heterozygous FCS-gene carriers will need APOC3-targeted therapy; on the bench, a novel SPP2–LPL axis offers a new handle on triglyceride homeostasis.]]></description>
      <pubDate>Fri, 19 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-19</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-19.mp3"
        length="11858400"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday June 19, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday June 16, 2026</title>
      <description><![CDATA[A meta-analysis confirms olezarsen's strong efficacy across eight RCTs, a human kinetic study illuminates exactly how ANGPTL3 deficiency reshapes triglyceride-rich lipoprotein metabolism, and a JACC case report highlights the management challenges of severe HTG in pregnancy — while the industry stage is quiet mid-week but poised for major events: the FDA PDUFA date for Tryngolza in sHTG arrives June 30, and Arrowhead's SHASTA-3/4 phase 3 readout is expected this month.]]></description>
      <pubDate>Tue, 16 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-16</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-16.mp3"
        length="9051360"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday June 16, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday June 12, 2026</title>
      <description><![CDATA[A quiet cycle on both fronts — no new top-tier lipid papers cleared the bar (the one journal hit, a Lancet D&E retrospective, was already covered Tuesday), and no fresh trade-press stories landed in the 5-day window, leaving the competitive backdrop dominated by the countdown to the FDA's June 30 decision on olezarsen in severe hypertriglyceridemia.]]></description>
      <pubDate>Fri, 12 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-12</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-12.mp3"
        length="5621760"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday June 12, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday June 9, 2026</title>
      <description><![CDATA[A sweeping 25-year review of lipid medicine published today in *Lancet Diabetes & Endocrinology* maps the journey from statins to RNA/DNA-targeted therapies for APOC3 and ANGPTL3; on the industry side, it's a quiet news week, but the Ionis FDA clock for Tryngolza in severe hypertriglyceridemia is now ticking down to a June 30 decision.]]></description>
      <pubDate>Tue, 09 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-09</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-09.mp3"
        length="8465760"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday June 9, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday June 5, 2026</title>
      <description><![CDATA[Circulation Research publishes a landmark trio of review articles on triglyceride-rich lipoprotein biology and RNA-targeted therapies today, while on the industry side it is a quiet week — but the Ionis Tryngolza FDA decision in sHTG is now just 25 days away and Arrowhead's SHASTA-3/4 phase 3 readouts are imminent.]]></description>
      <pubDate>Fri, 05 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-05</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-05.mp3"
        length="9435360"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday June 5, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday June 2, 2026</title>
      <description><![CDATA[A PNAS study reveals GPIHBP1 on brain oligodendrocytes as a novel docking site for LPL in the CNS, while an updated meta-analysis consolidates olezarsen's case as a potent APOC3-targeting therapy; on the industry side, a quiet week ahead of Ionis' looming June 30 FDA decision for Tryngolza in sHTG.]]></description>
      <pubDate>Tue, 02 Jun 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-06-02</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-06-02.mp3"
        length="2452224"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday June 2, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday May 29, 2026</title>
      <description><![CDATA[A quiet week on top-tier journal lipid papers, but four solid next-tier publications span plozasiran's approval story, a machine-learning breakthrough for predicting which HTG patients will develop pancreatitis, lipidomic signatures of drug-refractory HTG, and pediatric monogenic HTG genetics; on the industry side, Ionis's platform scores a landmark hepatitis B win this week, keeping the ASO powerhouse in the spotlight while its Tryngolza sHTG approval decision looms by June 30.]]></description>
      <pubDate>Fri, 29 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-29</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-29.mp3"
        length="3773184"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday May 29, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday May 26, 2026</title>
      <description><![CDATA[A landmark Circulation imaging trial finds that olezarsen's dramatic triglyceride lowering does not translate into coronary plaque regression at 12 months—raising fundamental questions about TG-lowering as an atherosclerosis therapy just as the 2026 ACC/AHA dyslipidemia guideline reframes how we should think about hypertriglyceridemia, and with Ionis's PDUFA date for the SHTG indication just five weeks away.]]></description>
      <pubDate>Tue, 26 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-26</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-26.mp3"
        length="9699840"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday May 26, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday May 22, 2026</title>
      <description><![CDATA[A landmark ACC/AHA dyslipidemia guideline dropped this week alongside a pivotal Circulation imaging trial showing olezarsen's dramatic triglyceride reduction does not translate into coronary plaque regression — a sobering finding that reframes what APOC3 inhibition can and cannot achieve at 12 months; on the industry side, the two biggest near-term catalysts remain Ionis' June 30 PDUFA date for olezarsen in sHTG and Arrowhead's expected EU approval of REDEMPLO, both just outside this cycle's lookback window but essential context.]]></description>
      <pubDate>Fri, 22 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-22</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-22.mp3"
        length="11055360"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday May 22, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday May 19, 2026</title>
      <description><![CDATA[A landmark Circulation imaging trial shows olezarsen dramatically lowers triglycerides but does not shrink coronary plaque, while two new meta-analyses confirm robust TG and pancreatitis benefits across the ApoC-III inhibitor class, and on the industry side both Arrowhead and Ionis are sprinting toward a mid-2026 collision in the sHTG market.]]></description>
      <pubDate>Tue, 19 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-19</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-19.mp3"
        length="11550935"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday May 19, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday May 15, 2026</title>
      <description><![CDATA[A quiet top-tier journal week — no NEJM/Lancet/JAMA hits, but the next tier delivered three substantial APOC3-inhibitor meta-analyses (olezarsen, plozasiran, and the full ApoC-III class) all landing the same message: large triglyceride drops and a dramatic ~80% cut in acute pancreatitis risk, plus a new HNF4A–SPP2–LPL axis that could expand the SHTG target list; the industry side was equally subdued, dominated by Madrigal's $1B-biobucks pickup of an Arrowhead RNAi MASH asset and the run-up to Ionis' Tryngolza sHTG PDUFA at the end of June.]]></description>
      <pubDate>Fri, 15 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-15</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-15.mp3"
        length="10406400"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday May 15, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday May 12, 2026</title>
      <description><![CDATA[A thin top-tier journal week pushed Part A to the next-best tier, where ApoC-III inhibitors keep stacking up favorable meta-analytic evidence and a new HNF4A–SPP2–LPL axis hints at fresh small-molecule entry points; the industry side is also quiet — the dominant story over the past seven days remains the run-up to the late-June Tryngolza sHTG PDUFA, with no major company-specific lipid news from the allowed outlets.]]></description>
      <pubDate>Tue, 12 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-12</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-12.mp3"
        length="9862080"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday May 12, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday May 8, 2026</title>
      <description><![CDATA[No top-tier journal hits surfaced this week — showing the next-best tier — but the haul is unusually substantive: the first randomized evidence that an APOC3 siRNA (plozasiran) prevents recurrent pancreatitis in very severe hypertriglyceridemia, a major Hegele review repositioning ANGPTL3 as a remnant-cholesterol target, and new human data linking ANGPTL3/4/8 complexes to heart failure outcomes.]]></description>
      <pubDate>Fri, 08 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-08</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-08.mp3"
        length="7632000"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday May 8, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Tuesday May 5, 2026</title>
      <description><![CDATA[A genuinely consequential week — the 2026 ACC/AHA dyslipidemia guideline lands in Circulation and explicitly incorporates hypertriglyceridemia and Lp(a) management, while NEJM publishes a three-letter correspondence exchange that pressure-tests the CORE-TIMI 72 olezarsen pancreatitis data.]]></description>
      <pubDate>Tue, 05 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-05</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-05.mp3"
        length="6658080"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Tuesday May 5, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Monday May 4, 2026</title>
      <description><![CDATA[This week's top-tier literature is anchored by the new 2026 ACC/AHA Dyslipidemia Guideline — the most comprehensive update to U.S. lipid management in eight years — alongside a cluster of NEJM correspondence debating the landmark olezarsen APOC3-targeting RCT and its implications for pancreatitis prevention in severe hypertriglyceridemia.]]></description>
      <pubDate>Mon, 04 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-04</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-04.mp3"
        length="2854217"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Monday May 4, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Sunday May 3, 2026</title>
      <description><![CDATA[A thin but consequential week — the new 2026 ACC/AHA multisociety dyslipidemia guideline lands in Circulation with hypertriglyceridemia and Lp(a) carved out as first-class targets, and three NEJM correspondence pieces continue the post-publication debate over olezarsen's pancreatitis benefit in severe hypertriglyceridemia.]]></description>
      <pubDate>Sun, 03 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-03</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-03.mp3"
        length="5303712"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Sunday May 3, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Saturday May 2, 2026</title>
      <description><![CDATA[A quiet week for new mechanistic and trial data, but two notable items: the 2026 ACC/AHA dyslipidemia guideline drops in Circulation (now formally folding hypertriglyceridemia into the same document as cholesterol), and three independent correspondence letters in NEJM probe the olezarsen pancreatitis-risk findings reported earlier this year by the TIMI group.]]></description>
      <pubDate>Sat, 02 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-02</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-02.mp3"
        length="6413280"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Saturday May 2, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday May 1, 2026</title>
      <description><![CDATA[A thin original-research week, but two genuinely high-impact items: the new joint 2026 ACC/AHA dyslipidemia guideline (which now formally addresses hypertriglyceridemia and Lp(a) alongside LDL-C), and three published letters in NEJM debating the CORE-TIMI 72a/b olezarsen trial — including the Marston/Bergmark/Sabatine reply.]]></description>
      <pubDate>Fri, 01 May 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-05-01</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-05-01.mp3"
        length="7450080"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday May 1, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Thursday April 30, 2026</title>
      <description><![CDATA[A thin but consequential week — the new 2026 ACC/AHA dyslipidemia guideline lands in *Circulation* and explicitly folds hypertriglyceridemia into the cholesterol-management framework, while *NEJM* publishes a correspondence cluster pressure-testing the pancreatitis-risk findings of the pivotal olezarsen (APOC3) trial.]]></description>
      <pubDate>Thu, 30 Apr 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-04-30</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-04-30.mp3"
        length="7085280"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Thursday April 30, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
    <item>
      <title>SHTG Digest — Friday April 24, 2026</title>
      <description><![CDATA[The week's literature is dominated by meta-analytic syntheses of APOC3-targeting agents (olezarsen and plozasiran) and ANGPTL3 inhibitors, converging on a consistent message — both pathways produce profound TG lowering with acceptable safety profiles, and plozasiran in particular now has the first prospective RCT evidence for reducing recurrent acute pancreatitis in FCS patients.]]></description>
      <pubDate>Fri, 24 Apr 2026 06:00:00 -0000</pubDate>
      <guid isPermaLink="false">shtg-digest-2026-04-24</guid>
      <enclosure
        url="https://d26qmx46pp-gif.github.io/MAREA_SHTG_DAILY/episodes/shtg-podcast-2026-04-24.mp3"
        length="3547136"
        type="audio/mpeg"/>
      <itunes:title>SHTG Digest — Friday April 24, 2026</itunes:title>
      <itunes:duration>7:00</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:explicit>false</itunes:explicit>
    </item>
  </channel>
</rss>
